Inherited DNA Repair Defects in Colorectal Cancer

Colorectal cancer (CRC) heritability has been estimated to be around 30%. However, mutations in the known CRC-susceptibility genes explain CRC risk in fewer than 10% of affected individuals. Germline mutations in DNA-repair genes (DRGs) have recently been reported in CRC, but their contribution to CRC risk is largely unknown. We evaluated the gene-level germline mutation enrichment of 40 DRGs in 680 unselected CRC individuals and 27,728 ancestry-matched cancer-free adults. Significant findings were then examined in independent cohorts of 1,661 unselected CRC individuals and 1,456 individuals with early-onset CRC. Of the 680 individuals in the discovery set, 31 (4.56%) individuals harbored germline pathogenic mutations in known CRC-susceptibility genes, and another 33 (4.85%) individuals had DRG mutations that have not been previously associated with CRC risk. Germline pathogenic mutations in ATM and PALB2 were enriched in both the discovery (OR = 2.81 and p = 0.035 for ATM and OR = 4.91 and p = 0.024 for PALB2) and validation (OR = 2.97 and adjusted p = 0.0013 for ATM and OR = 3.42 and adjusted p = 0.034 for PALB2) sets. Biallelic loss of ATM was evident in all individuals with matched tumor profiling. CRC individuals also had higher rates of actionable mutations in the HR pathway, which can substantially increase the risk of developing cancers other than CRC. Our analysis provides evidence for ATM and PALB2 as CRC-risk genes, underscoring the importance of the homologous recombination pathway in CRC. In addition, we identified frequent complete homologous recombination deficiency in CRC tumors, representing a unique opportunity to explore targeted therapeutic interventions such as poly-ADP ribose polymerase inhibitor (PARPi).

[1]  H T Lynch,et al.  Hereditary colorectal cancer. , 1991, Seminars in oncology.

[2]  Z. Cohen,et al.  Genetic testing for Lynch syndrome in the province of Ontario , 2016, Cancer.

[3]  D. Ward,et al.  Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancer , 1994, Nature.

[4]  Wendy S. W. Wong,et al.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs , 2012, Bioinform..

[5]  Carrie Cibulskis,et al.  Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study , 2017, Genetics in Medicine.

[6]  S. Syngal,et al.  Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. , 2015, Gastroenterology.

[7]  Jill S Barnholtz-Sloan,et al.  Ancestry Estimation and Correction for Population Stratification in Molecular Epidemiologic Association Studies , 2008, Cancer Epidemiology Biomarkers & Prevention.

[8]  Diana Eccles,et al.  Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. , 2013, Journal of the National Cancer Institute.

[9]  I. Pe’er,et al.  Optimal two‐stage genotyping designs for genome‐wide association scans , 2006, Genetic epidemiology.

[10]  G. Iliakis,et al.  DNA double-strand-break repair in higher eukaryotes and its role in genomic instability and cancer: Cell cycle and proliferation-dependent regulation. , 2016, Seminars in cancer biology.

[11]  A. Sivachenko,et al.  Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples , 2013, Nature Biotechnology.

[12]  James Y. Zou.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[13]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[14]  Chen Wang,et al.  ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib1 , 2017, Translational oncology.

[15]  Minoru Kanehisa,et al.  KEGG as a reference resource for gene and protein annotation , 2015, Nucleic Acids Res..

[16]  Michele L Cote,et al.  BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study , 2014, Genetics in Medicine.

[17]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[18]  A. Taylor,et al.  Health risks for ataxia‐telangiectasia mutated heterozygotes: a systematic review, meta‐analysis and evidence‐based guideline , 2016, Clinical genetics.

[19]  Alison L. Livingston,et al.  Inherited variants of MYH associated with somatic G:C→T:A mutations in colorectal tumors , 2002, Nature Genetics.

[20]  N. Copeland,et al.  The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer , 1993, Cell.

[21]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[22]  A. Børresen-Dale,et al.  Breast and other cancers in 1445 blood relatives of 75 Nordic patients with ataxia telangiectasia , 2005, British Journal of Cancer.

[23]  Wendy K Chung,et al.  Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing , 2015, Genetics in Medicine.

[24]  Nazneen Rahman,et al.  Breast-cancer risk in families with mutations in PALB2. , 2014, The New England journal of medicine.

[25]  Trevor J Pugh,et al.  Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.

[26]  A. McKenna,et al.  Absolute quantification of somatic DNA alterations in human cancer , 2012, Nature Biotechnology.

[27]  Adam Kiezun,et al.  Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.

[28]  A. Gylfason,et al.  Mutations in BRIP1 confer high risk of ovarian cancer , 2011, Nature Genetics.

[29]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[30]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[31]  P. Oefner,et al.  Rare variants in the ATM gene and risk of breast cancer , 2011, Breast Cancer Research.

[32]  A. Gylfason,et al.  Loss-of-function variants in ATM confer risk of gastric cancer , 2015, Nature Genetics.

[33]  L. Garraway,et al.  Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study , 2016, Genetics in Medicine.

[34]  P. Goodfellow,et al.  Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer , 2017, JAMA oncology.

[35]  Hajime Uno,et al.  Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[37]  R. Elston,et al.  One-stage versus two-stage strategies for genome scans. , 2001, Advances in genetics.

[38]  Ahmet Zehir,et al.  Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.

[39]  G. Parmigiani,et al.  Familial Risk and Heritability of Cancer Among Twins in Nordic Countries. , 2016, JAMA.

[40]  S. Gabriel,et al.  Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma , 2016, Cell reports.

[41]  Tesfaye B Mersha,et al.  Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities , 2015, Human Genomics.

[42]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[43]  P. Broderick,et al.  Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer , 2016, Nature Communications.

[44]  Lesley McGuffog,et al.  Cancer risks and mortality in heterozygous ATM mutation carriers. , 2005, Journal of the National Cancer Institute.

[45]  P. Visscher,et al.  New mutations, old statistical challenges , 2017, bioRxiv.

[46]  P. Møller,et al.  The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers , 2012, British Journal of Cancer.

[47]  Trevor J Pugh,et al.  Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation , 2013, Nucleic acids research.

[48]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[49]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer , 2011, Nature Biotechnology.

[50]  Li Ding,et al.  Germline Mutations in Predisposition Genes in Pediatric Cancer. , 2015, The New England journal of medicine.